News & Updates

Ventricular tachycardia predicts all-cause death and non-sudden cardiovascular death (NSCVD) in patients with non-ischaemic cardiomyopathy, a study suggests.

For cancer patients with depression, treatment with a single dose of psilocybin appears to yield rapid and meaningful improvements in depressive symptoms, as shown in a phase II study.

Patients with severe COVID-19 requiring mechanical ventilation are 16 times more likely to develop ventricular tachycardia (V-tach) within 6 months following discharge compared with matched controls without severe infection in a Swedish case-control study presented at EHRA 2023.

Ten-day treatment with vonoprazan 20 mg twice/day plus amoxicillin 750 mg four times/day (VHA-dual) as a first-line therapy for Helicobacter pylori infection results in satisfactory eradication rate of >90 percent, fewer adverse events (AEs), and similar adherence when compared with bismuth quadruple therapy (B-quadruple), results of a study have shown.

Sleep disruption following hospital admission for COVID-19 is associated with dyspnoea, anxiety, and muscle weakness in the CircCOVID cohort sub-study presented at ECCMID 2023.

Individuals who have contracted COVID-19 at increased risk of developing irritable bowel syndrome (IBS) compared with those who have not been infected, as reported in a study.